Modern cancer drugs more likely to get to market
LONDON (Reuters) - Nearly one in five cancer drugs entering development now reach the market, a remarkably good success rate given the high level of failures in other disease areas, British researchers said on Friday .<div class="feedflare">
<img src="http://feedproxy.google.com/~f/reuters/scienceNews?d=41" border="0"></img> (http://feeds.reuters.com/~f/reuters/scienceNews?a=YsdPG14n) <img src="http://feedproxy.google.com/~f/reuters/scienceNews?i=fj7Je6UI" border="0"></img> (http://feeds.reuters.com/~f/reuters/scienceNews?a=fj7Je6UI) <img src="http://feedproxy.google.com/~f/reuters/scienceNews?i=K1Y2zeWo" border="0"></img> (http://feeds.reuters.com/~f/reuters/scienceNews?a=K1Y2zeWo)
</div><img src="http://feedproxy.google.com/~r/reuters/scienceNews/~4/NB6wilfuw8M" height="1" width="1"/>
http://feeds.reuters.com/~r/reuters/scienceNews/~3/NB6wilfuw8M/idUSTRE4AD4QW20081114